Integrins are a major family of cell surface receptors that modulate cell adhesion, migration, proliferation and survival through interaction with the extracellular matrix (ECM) and the actin cytoskeleton. Integrins are type 1 transmembrane proteins that exist at the cell surface as heterodimers of alpha and beta subunits, of which there are 18 and 8 different isoforms, respectively, in human cells. In addition to their mechanical role in mediating contact between the ECM and the cytoskeleton, integrins also modulate intracellular signaling pathways governing cytoskeletal rearrangements and pro-survival and mitogenic signaling (reviewed in Hehlgans et al, 2007; Harburger and Calderwood, 2009; Ata and Antonescu, 2017). In this pathway, we describe signaling through integrin alphaIIb beta3 as a representative example.
At the sites of vascular injury bioactive molecules such as thrombin, ADP, collagen, fibrinogen and thrombospondin are generated, secreted or exposed. These stimuli activate platelets, converting the major platelet integrin alphaIIbbeta3 from a resting state to an active conformation, in a process termed integrin priming or 'inside-out signalling'. Integrin activation refers to the change required to enhance ligand-binding activity. The activated alphaIIbbeta3 interacts with the fibrinogen and links platelets together in an aggregate to form a platelet plug. AlphaIIbbeta3 bound to fibrin generates more intracellular signals (outside-in signalling), causing further platelet activation and platelet-plug retraction. In the resting state the alpha and beta tails are close together. This interaction keeps the membrane proximal regions in a bent conformation that maintains alphaIIbbeta3 in a low affinity state. Integrin alphaIIbbeta3 is released from its inactive state by interaction with the protein talin. Talin interacts with the beta3 cytoplasmic domain and disrupts the salt bridge between the alpha and beta chains. This separation in the cytoplasmic regions triggers the conformational change in the extracellular domain that increases its affinity to fibrinogen. Much of talin exists in an inactive cytosolic pool, and the Rap1 interacting adaptor molecule (RIAM) is implicated in talin activation and translocation to beta3 integrin cytoplasmic domain.
Vuori K, Hirai H, Aizawa S, Ruoslahti E.; ''Introduction of p130cas signaling complex formation upon integrin-mediated cell adhesion: a role for Src family kinases.''; PubMedEurope PMCScholia
Pesho MM, Bledzka K, Michalec L, Cierniewski CS, Plow EF.; ''The specificity and function of the metal-binding sites in the integrin beta3 A-domain.''; PubMedEurope PMCScholia
Law DA, Nannizzi-Alaimo L, Phillips DR.; ''Outside-in integrin signal transduction. Alpha IIb beta 3-(GP IIb IIIa) tyrosine phosphorylation induced by platelet aggregation.''; PubMedEurope PMCScholia
Lafuente EM, van Puijenbroek AA, Krause M, Carman CV, Freeman GJ, Berezovskaya A, Constantine E, Springer TA, Gertler FB, Boussiotis VA.; ''RIAM, an Ena/VASP and Profilin ligand, interacts with Rap1-GTP and mediates Rap1-induced adhesion.''; PubMedEurope PMCScholia
Kasirer-Friede A, Kahn ML, Shattil SJ.; ''Platelet integrins and immunoreceptors.''; PubMedEurope PMCScholia
Litvinov RI, Bennett JS, Weisel JW, Shuman H.; ''Multi-step fibrinogen binding to the integrin (alpha)IIb(beta)3 detected using force spectroscopy.''; PubMedEurope PMCScholia
Nakamoto T, Sakai R, Ozawa K, Yazaki Y, Hirai H.; ''Direct binding of C-terminal region of p130Cas to SH2 and SH3 domains of Src kinase.''; PubMedEurope PMCScholia
Defilippi P, Di Stefano P, Cabodi S.; ''p130Cas: a versatile scaffold in signaling networks.''; PubMedEurope PMCScholia
Crittenden JR, Bergmeier W, Zhang Y, Piffath CL, Liang Y, Wagner DD, Housman DE, Graybiel AM.; ''CalDAG-GEFI integrates signaling for platelet aggregation and thrombus formation.''; PubMedEurope PMCScholia
Arias-Salgado EG, Haj F, Dubois C, Moran B, Kasirer-Friede A, Furie BC, Furie B, Neel BG, Shattil SJ.; ''PTP-1B is an essential positive regulator of platelet integrin signaling.''; PubMedEurope PMCScholia
Lafuente E, Boussiotis VA.; ''Rap1 regulation of RIAM and cell adhesion.''; PubMedEurope PMCScholia
Wegener KL, Partridge AW, Han J, Pickford AR, Liddington RC, Ginsberg MH, Campbell ID.; ''Structural basis of integrin activation by talin.''; PubMedEurope PMCScholia
Li R, Bennett JS, Degrado WF.; ''Structural basis for integrin alphaIIbbeta3 clustering.''; PubMedEurope PMCScholia
Obergfell A, Eto K, Mocsai A, Buensuceso C, Moores SL, Brugge JS, Lowell CA, Shattil SJ.; ''Coordinate interactions of Csk, Src, and Syk kinases with [alpha]IIb[beta]3 initiate integrin signaling to the cytoskeleton.''; PubMedEurope PMCScholia
Shattil SJ.; ''Integrins and Src: dynamic duo of adhesion signaling.''; PubMedEurope PMCScholia
Ata R, Antonescu CN.; ''Integrins and Cell Metabolism: An Intimate Relationship Impacting Cancer.''; PubMedEurope PMCScholia
Watson SP, Auger JM, McCarty OJ, Pearce AC.; ''GPVI and integrin alphaIIb beta3 signaling in platelets.''; PubMedEurope PMCScholia
Shattil SJ, Newman PJ.; ''Integrins: dynamic scaffolds for adhesion and signaling in platelets.''; PubMedEurope PMCScholia
Schaller MD.; ''Biochemical signals and biological responses elicited by the focal adhesion kinase.''; PubMedEurope PMCScholia
Cowan KJ, Law DA, Phillips DR.; ''Identification of shc as the primary protein binding to the tyrosine-phosphorylated beta 3 subunit of alpha IIbbeta 3 during outside-in integrin platelet signaling.''; PubMedEurope PMCScholia
Okada M, Nada S, Yamanashi Y, Yamamoto T, Nakagawa H.; ''CSK: a protein-tyrosine kinase involved in regulation of src family kinases.''; PubMedEurope PMCScholia
Schlaepfer DD, Jones KC, Hunter T.; ''Multiple Grb2-mediated integrin-stimulated signaling pathways to ERK2/mitogen-activated protein kinase: summation of both c-Src- and focal adhesion kinase-initiated tyrosine phosphorylation events.''; PubMedEurope PMCScholia
Bonfini L, Migliaccio E, Pelicci G, Lanfrancone L, Pelicci PG.; ''Not all Shc's roads lead to Ras.''; PubMedEurope PMCScholia
Kurosaki T, Takata M, Yamanashi Y, Inazu T, Taniguchi T, Yamamoto T, Yamamura H.; ''Syk activation by the Src-family tyrosine kinase in the B cell receptor signaling.''; PubMedEurope PMCScholia
Gao J, Zoller KE, Ginsberg MH, Brugge JS, Shattil SJ.; ''Regulation of the pp72syk protein tyrosine kinase by platelet integrin alpha IIb beta 3.''; PubMedEurope PMCScholia
Parise LV.; ''Integrin alpha(IIb)beta(3) signaling in platelet adhesion and aggregation.''; PubMedEurope PMCScholia
Shattil SJ.; ''Signaling through platelet integrin alpha IIb beta 3: inside-out, outside-in, and sideways.''; PubMedEurope PMCScholia
Andjelković M, Alessi DR, Meier R, Fernandez A, Lamb NJ, Frech M, Cron P, Cohen P, Lucocq JM, Hemmings BA.; ''Role of translocation in the activation and function of protein kinase B.''; PubMedEurope PMCScholia
Kirk RI, Sanderson MR, Lerea KM.; ''Threonine phosphorylation of the beta 3 integrin cytoplasmic tail, at a site recognized by PDK1 and Akt/PKB in vitro, regulates Shc binding.''; PubMedEurope PMCScholia
Mochizuki N, Ohba Y, Kobayashi S, Otsuka N, Graybiel AM, Tanaka S, Matsuda M.; ''Crk activation of JNK via C3G and R-Ras.''; PubMedEurope PMCScholia
Giuliano S, Nesbitt WS, Rooney M, Jackson SP.; ''Bidirectional integrin alphaIIbbeta3 signalling regulating platelet adhesion under flow: contribution of protein kinase C.''; PubMedEurope PMCScholia
Stork PJ, Dillon TJ.; ''Multiple roles of Rap1 in hematopoietic cells: complementary versus antagonistic functions.''; PubMedEurope PMCScholia
Andjelković M, Maira SM, Cron P, Parker PJ, Hemmings BA.; ''Domain swapping used to investigate the mechanism of protein kinase B regulation by 3-phosphoinositide-dependent protein kinase 1 and Ser473 kinase.''; PubMedEurope PMCScholia
Syed NA, Horner KN, Misra V, Khandelwal RL.; ''Different cellular localization, translocation, and insulin-induced phosphorylation of PKBalpha in HepG2 cells and hepatocytes.''; PubMedEurope PMCScholia
Schlaepfer DD, Hanks SK, Hunter T, van der Geer P.; ''Integrin-mediated signal transduction linked to Ras pathway by GRB2 binding to focal adhesion kinase.''; PubMedEurope PMCScholia
Relou IA, Bax LA, van Rijn HJ, Akkerman JW.; ''Site-specific phosphorylation of platelet focal adhesion kinase by low-density lipoprotein.''; PubMedEurope PMCScholia
Arold ST, Hoellerer MK, Noble ME.; ''The structural basis of localization and signaling by the focal adhesion targeting domain.''; PubMedEurope PMCScholia
Upon the production of activated Rap1A at the plasma membrane, RIAM interacts with Rap1A-GTP with its N-ter RA domain, and with its C-ter PH domain it interacts with PIP2.
As integrins do not have an intrinsic catalytic activity, the signals initiated by the ECM-integrin interactions are transduced into cells through the integrin bound protein-tyrosine kinases. PTK2 (protein-tyrosine kinase 2, also known as Focal adhesion kinase 1; FADK1, FAK) is one of the protein tyrosine kinases that plays a prominent role in integrin signaling. PTK2 has been implicated in controlling cell motility and transmitting a cell survival signal from ECM.
PTK2 is recruited to sites of integrin clustering by directly binding to integrin associated c-Src.
The co-localization of PTK2/FAK with integrins in focal adhesions and the actin cytoskeleton is essential for the activation and phosphorylation of PTK2/FAK. PTK2/FAK has six tyrosine phosphorylation sites and tyrosine 397 is the main auto-phosphorylation site present upstream of the kinase domain.
The interaction between talin and integrin alphaIIb beta3 breaks the putative salt bridge between the alphaIIb (R995) and beta3 (D723) integrin chains and induces conformational changes in their external domains increasing their affinity for fibrinogen and other ECM ligands. Breaking of this salt bridge is necessary but not sufficient for full activation. The Talin F3 subdomain of the FERM domain has a phosphotyrosine binding (PTB) domain fold. This domain interacts with the membrane-proximal (MP) region within the integrin beta3 chain. The primary function of this interaction is to provide an initial strong linkage between talin and integrin and this interaction holds the key to the molecular recognition required for activation. In platelets SRC kinase and its negative regulator CSK associates constitutively with integrin alphaIIbbeta3. SRC is involved in alphaIIbbeta3 dependent activation of SYK, and both SRC and SYK are required to initiate cytoskeletal events responsible for platelet spreading on fibrinogen.
Phosphorylated tyrosine 925 in the FAT domain of PTK2/FAK creates a docking site for the SH2 domain of GRB2 and recruits the GRB2/SOS complex. PTK2 may use this mechanism to activate Ras and the MAP kinase pathway.
Talin is one of the major cytoskeletal proteins involved in integrin activation and linking the resulting focal adhesion (FA) with cytoskeleton. Talin comprises an N-ter head region and a flexible rod domain. The head region has the FERM domain (subdivided into F1, F2 and F3 subdomains), which has the binding sites for beta integrin cytoplasmic regions and actin binding sites close to the C-terminal rod domain. Talin exists in closed inactive conformation, where the head region interacts with the rod domain masking the integrin binding sites. At the plasma membrane the RIAM bound to active Rap1 recruits talin to form the integrin activation complex. This interaction exposes the integrin-binding site in talin F3 domain leading to integrin activation.
The recruitment of FADK1 to active SRC leads to the efficient tyrosine phosphorylation of multiple additional sites on FADK1. SRC trans-phosphorylates FADK1 within the kinase doman activation loop (Y576 and Y577) and within the FADK1 C-terminal domain (Y861 and Y925).
The overall shape of integrins is that of a globular 'head' supported by two rod like legs. The ligand-binding pocket is formed by the combination of A-domain or beta-I domain on the beta3 subunit and the putative beta-propeller fold on the alphaIIb subunit in the head regions. The binding of ligand to integrin is also dependent on divalent cations (usually Mn++ or Mg++or Ca++). A conserved motif, the metal ion-dependant adhesion site (MIDAS) is located in the alpha and the beta chains that coordinate the divalent cation at the top of the domain. Active integrin alphaIIb beta3 interacts with a variety of plasma proteins such as fibrinogen, vWF, thrombin, thrombospondin, and fibronectin. The ability of alphaIIbbeta3 to bind fibrinogen plays a crucial role in platelet aggregation and hemostasis. Most of these matrix proteins have integrin binding sites of 3-6 amino acids length, of which the best known are the 'RGD' and 'KGD' motifs. The alpha and beta integrin subunits are both required for ligand binding.
Son of sevenless protein homolog 1(SOS) is an activating nucleotide exchange factor for H-Ras (p21Ras). SOS is brought close to the H-Ras by interacting with the FADK1 bound GRB2.
Signals from agonist receptors (such as GPVI) trigger the production of PIP3, DAG, cAMP and elevated Ca++ levels. This leads to the activation and translocation of active Rap1-GTP to the plasma membrane. Rap-GEFs stimulate the replacement of GDP for GTP, activating Rap1. Several Rap1 GEFs have been identified enabling Rap1 to respond to diverse stimuli. CalDAG-GEFs activate Rap1 in response to calcium and DAG, downstream of Phospholipase C. EPAC (exchange proteins directly activated by cAMP) GEFs are activated by binding cAMP.
SH3-mediated binding of BCAR1/p130Cas to PTK2 is linked to enhanced tyrosine phosphorylation of BCAR1 at multiple sites. The Cas substrate domain contains 15 separate YxxP motifs, a main site of tyrosine phosphorylation on the BCAR1 molecule. Once phosphorylated, this domain serves as a docking site for the SH2 domains of CRK or NCK adaptor proteins that affect the downstream MAPK signalling pathway, resulting in cell survival and increased motility.
Crk is an adaptor protein with one SH2 and two SH3 domains. It is involved in integrin mediated signalling and is recruited to the focal adhesion complexes by interacting with p130Cas or paxillin through its SH2 domain.
BCAR1 (breast cancer anti-estrogen resistance protein1, also known as Crk-associated substrate (Cas) or p130Cas) is an adaptor protein that promotes protein-protein interactions, leading to the multiprotein complexes. The interaction of ?BCAR1/p130Cas with other proteins modulates cell motility, survial and proliferation. BCAR1/P130Cas is one of the main phosphorylation targets of the PTK2/SRC complex. The BCAR1 SH3 domain binds to PR1 and PR2 (‘PxxP’) domains in the PTK2 C-terminal domain.
Clustering of Integrin alphaIIb beta3 complexes results in the trans auto-phosphorylation of SRC tyrosine residue 419 (often referred to as 418 in the literature, as the initiating methionine is cleaved in the mature peptide) in SRC's kinase activation loop.
The fibrinogen-bound integrin alphaIIb beta3 clusters platelets together to form a platelet plug and generates intracellular signals (outside-in) causing further platelet activation and platelet plug retraction. Intracellular integrin alphaIIb beta3 clustering brings SRCs bound to integrin beta3 chains into proximity. SRC associates constitutively with integrin alphaIIb beta3. In unstimulated cells this SRC is inactive, auto-inhibited by an internal interaction between phosphorylated Y530 and the SH2 domain. CSK is selective for the Y530 residue and prevents access to SRC of PTP1B, a protein tyrosine phosphatase that is capable of de-phosphorylating Y530.
The integrin alphaIIb beta3:Inactive SRC complex recruits PTP1B protein tyrosine phosphatase resulting in the dephosphorylation of SRC tyrosine 530. The phosphorylated tail of SRC tail interacts with the SH2 domain thereby repressing kinase activity; removal of phosphorylation activates SRC kinase activity.
CSK bound to integrin alphaIIb beta3 negatively regulates SRC by phosphorylating the Tyr-530. Platelet adhesion to fibrinogen causes the disassociation of CSK from alphaIIb beta3 complex.
Integrin alphaIIb beta3 'outside-in' signalling involves multiple proteins including SRC, SYK, SLP-76 and PLCgamma2. SRC is constitutively associated with the C-terminal tail of integrin beta 3. SYK is recruited to the beta3 tail and subsequently activated by SRC.
SYK activation in integrin signalling is associated with increased tyrosine phosphorylation. SYK activation and phosphorylation of SYK targets can be blocked by SRC inhibitors or expression of dominant negative SRC mutants.
The beta 3 integrin cytoplasmic tail binds SH2-containing protein (SHC), an adapter in Ras signaling. Phosphorylation of Y785 may be necessary for binding; phosphorylation of T779 inhibits SHC binding. Mice expressing a mutated beta 3 where Y773 and Y785 have been mutated to F exhibit rebleeding from tail wounds and subtle defects in clot retraction and platelet aggregation.
The binding of SHC to integrin alpha IIb beta 3 is blocked by phosphorylation of beta 3 at Thr-779, or by substitution of this residue for Asp. PDK1 and Akt1/PKB-alpha both specifically target Thr-779 in in vitro assays.
In a mechanism that is presumed to be analagous to signaling of SHC downstream of the insulin and TrkA receptors, SHC becomes phosphorylated and dissociates from the integrin alphaIIb beta3 complex.
In a mechanism that is presumed to be analagous to signaling of SHC downstream of the insulin and TrkA receptors, SHC becomes phosphorylated and dissociates from the integrin alphaIIb beta3 complex.
Signals from agonist receptors (such as GPVI) trigger the production of PIP3, DAG, cAMP and elevated Ca++ levels. This leads to the activation and translocation of active Rap1-GTP to the plasma membrane. Rap-GEFs stimulate the replacement of GDP for GTP, activating Rap1. Several Rap1 GEFs have been identified enabling Rap1 to respond to diverse stimuli. CalDAG-GEFs activate Rap1 in response to calcium and DAG, downstream of Phospholipase C. EPAC (exchange proteins directly activated by cAMP) GEFs are activated by binding cAMP.
Try the New WikiPathways
View approved pathways at the new wikipathways.org.Quality Tags
Ontology Terms
Bibliography
History
External references
DataNodes
ligands:alphaIIb beta3:p-Y419
SRC:p-6Y-PTK2alpha IIb beta
3:p-Y530-SRC:CSK:Talin:RIAM complex:p-Y427-SHCalphaIIb beta
3:p(Y530)-SRC:CSK:Talin:RIAM complex:SHCalphaIIb
beta3:p-Y530-SRC:CSK:Talin:RIAM complexalphaIIb
beta3:p-Y530-SRC:CSKcomplex:ECM ligands: 2X(Integrin alphaIIb beta3:Inactive
(p-Y530)-SRC)complex:ECM ligands: 2X(Integrin alphaIIb
beta3:p(Y530)-SRC:CSK)complex:ECM ligands: 2X(Integrin
alphaIIb beta3:SRC)complex:ECM ligands: Integrin alphaIIb beta3:Active
(p-Y419)-SRC:p-6Y-PTK2complex:ECM ligands: alphaIIb beta3:Active
p-Y419-SRC:pY397-PTK2complex:ECM ligands:2X(Integrin alphaIIb beta3:Active
p-Y419-SRC)ECM ligands:Integrin alphaIIb beta3:Active
(p-Y419)- SRC:PTK2ligands:2X (Integrin alphaIIb beta3:Active
(p-Y419)-SRC):SYKligands:2X(Integrin alphaIIb beta3:Active
(p-Y419)-SRC):p(Y)-SYKAnnotated Interactions
ligands:alphaIIb beta3:p-Y419
SRC:p-6Y-PTK2ligands:alphaIIb beta3:p-Y419
SRC:p-6Y-PTK2ligands:alphaIIb beta3:p-Y419
SRC:p-6Y-PTK2alpha IIb beta
3:p-Y530-SRC:CSK:Talin:RIAM complex:p-Y427-SHCalpha IIb beta
3:p-Y530-SRC:CSK:Talin:RIAM complex:p-Y427-SHCalphaIIb beta
3:p(Y530)-SRC:CSK:Talin:RIAM complex:SHCalphaIIb beta
3:p(Y530)-SRC:CSK:Talin:RIAM complex:SHCalphaIIb
beta3:p-Y530-SRC:CSK:Talin:RIAM complexalphaIIb
beta3:p-Y530-SRC:CSK:Talin:RIAM complexalphaIIb
beta3:p-Y530-SRC:CSK:Talin:RIAM complexalphaIIb
beta3:p-Y530-SRC:CSK:Talin:RIAM complexalphaIIb
beta3:p-Y530-SRC:CSKalphaIIb
beta3:p-Y530-SRC:CSKPTK2 is recruited to sites of integrin clustering by directly binding to integrin associated c-Src.
PTK2/FAK has six tyrosine phosphorylation sites and tyrosine 397 is the main auto-phosphorylation site present upstream of the kinase domain.
The Talin F3 subdomain of the FERM domain has a phosphotyrosine binding (PTB) domain fold. This domain interacts with the membrane-proximal (MP) region within the integrin beta3 chain. The primary function of this interaction is to provide an initial strong linkage between talin and integrin and this interaction holds the key to the molecular recognition required for activation. In platelets SRC kinase and its negative regulator CSK associates constitutively with integrin alphaIIbbeta3. SRC is involved in alphaIIbbeta3 dependent activation of SYK, and both SRC and SYK are required to initiate cytoskeletal events responsible for platelet spreading on fibrinogen.
Talin exists in closed inactive conformation, where the head region interacts with the rod domain masking the integrin binding sites. At the plasma membrane the RIAM bound to active Rap1 recruits talin to form the integrin activation complex. This interaction exposes the integrin-binding site in talin F3 domain leading to integrin activation.
Active integrin alphaIIb beta3 interacts with a variety of plasma proteins such as fibrinogen, vWF, thrombin, thrombospondin, and fibronectin. The ability of alphaIIbbeta3 to bind fibrinogen plays a crucial role in platelet aggregation and hemostasis. Most of these matrix proteins have integrin binding sites of 3-6 amino acids length, of which the best known are the 'RGD' and 'KGD' motifs. The alpha and beta integrin subunits are both required for ligand binding.
Intracellular integrin alphaIIb beta3 clustering brings SRCs bound to integrin beta3 chains into proximity. SRC associates constitutively with integrin alphaIIb beta3. In unstimulated cells this SRC is inactive, auto-inhibited by an internal interaction between phosphorylated Y530 and the SH2 domain. CSK is selective for the Y530 residue and prevents access to SRC of PTP1B, a protein tyrosine phosphatase that is capable of de-phosphorylating Y530.
complex:ECM ligands: 2X(Integrin alphaIIb beta3:Inactive
(p-Y530)-SRC)complex:ECM ligands: 2X(Integrin alphaIIb beta3:Inactive
(p-Y530)-SRC)complex:ECM ligands: 2X(Integrin alphaIIb
beta3:p(Y530)-SRC:CSK)complex:ECM ligands: 2X(Integrin alphaIIb
beta3:p(Y530)-SRC:CSK)complex:ECM ligands: 2X(Integrin
alphaIIb beta3:SRC)complex:ECM ligands: 2X(Integrin
alphaIIb beta3:SRC)complex:ECM ligands: Integrin alphaIIb beta3:Active
(p-Y419)-SRC:p-6Y-PTK2complex:ECM ligands: Integrin alphaIIb beta3:Active
(p-Y419)-SRC:p-6Y-PTK2complex:ECM ligands: Integrin alphaIIb beta3:Active
(p-Y419)-SRC:p-6Y-PTK2complex:ECM ligands: alphaIIb beta3:Active
p-Y419-SRC:pY397-PTK2complex:ECM ligands: alphaIIb beta3:Active
p-Y419-SRC:pY397-PTK2complex:ECM ligands: alphaIIb beta3:Active
p-Y419-SRC:pY397-PTK2complex:ECM ligands:2X(Integrin alphaIIb beta3:Active
p-Y419-SRC)complex:ECM ligands:2X(Integrin alphaIIb beta3:Active
p-Y419-SRC)complex:ECM ligands:2X(Integrin alphaIIb beta3:Active
p-Y419-SRC)ECM ligands:Integrin alphaIIb beta3:Active
(p-Y419)- SRC:PTK2ECM ligands:Integrin alphaIIb beta3:Active
(p-Y419)- SRC:PTK2ECM ligands:Integrin alphaIIb beta3:Active
(p-Y419)- SRC:PTK2ligands:2X (Integrin alphaIIb beta3:Active
(p-Y419)-SRC):SYKligands:2X (Integrin alphaIIb beta3:Active
(p-Y419)-SRC):SYKligands:2X (Integrin alphaIIb beta3:Active
(p-Y419)-SRC):SYKligands:2X(Integrin alphaIIb beta3:Active
(p-Y419)-SRC):p(Y)-SYK